Cellosaurus logo
expasy logo

Cellosaurus RPMI-8226 (CVCL_0014)

[Text version]
Cell line name RPMI-8226
Synonyms RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson
Accession CVCL_0014
Secondary accession CVCL_7353
Resource Identification Initiative To cite this cell line use: RPMI-8226 (RRID:CVCL_0014)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Part of: NCI-7 clinical proteomics reference material cell line panel.
Population: African American.
Characteristics: Produces IgG lambda (PubMed=6042436; ATCC=CCL-155).
Doubling time: 60 hours (PubMed=25984343); ~60-70 hours (DSMZ=ACC-402); 33.5 hours (NCI-DTP=RPMI-8226).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
Misspelling: RPMI-8266; Note=Occasionally.
Misspelling: RPMI-8826; Cosmic=875867.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: B-cell; CL=CL_0000236.
Sequence variations
HLA typing Source: PubMed=15748285
Class I
HLA-AA*30:01,68:02
HLA-BB*15:03,15:10
HLA-CC*02:02:04,03:04:02
Class II
HLA-DPDPB1*01:01:02,13:01
HLA-DQDQB1*02:01,02:02
HLA-DRDRB1*03:01:01,07:01

Source: PubMed=26589293
Class I
HLA-AA*30:01,68:02
HLA-BB*15:10,15:10
HLA-CC*02:02,03:04

Source: Direct_author_submission
Class I
HLA-AA*30,68:02
HLA-BB*15,15
HLA-CC*02:02,03:04

Source: DSMZCellDive=ACC-402
Class I
HLA-AA*30:01:01,68:02:01
HLA-BB*15:10:01,15:03:01
HLA-CC*02:10:01,03:04:02
Class II
HLA-DPDPA1*02:01:01,02:01:01
HLA-DRDRA*01:01:01,01:01:01
DRB1*03:01:01,07:01:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African73.94
Native American0
East Asian, North1.06
East Asian, South0
South Asian0
European, North11.76
European, South13.24
Disease Plasma cell myeloma (NCIt: C3242)
Multiple myeloma (ORDO: Orphanet_29073)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_9V32 (B6B11)CVCL_1862 (COLO 677)CVCL_1996 (COLO 775)
CVCL_3732 (KR-12)CVCL_A6KD (RF-S1)CVCL_A9CZ (RPMI-8226-EGFP)
CVCL_A9DA (RPMI-8226-Luc2-tdT)CVCL_A9DB (RPMI-8226-mCherry)CVCL_A9DC (RPMI-8226-tdT)
CVCL_XK17 (RPMI-8226-R)CVCL_J431 (RPMI-8226/Dox40)CVCL_J432 (RPMI-8226/Dox6)
CVCL_J434 (RPMI-8226/LR-5)CVCL_4V90 (RPMI-8226/MR4)
Sex of cell Male
Age at sampling 61Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=19372543; PubMed=25877200; TKG

Markers:
AmelogeninX (PubMed=19372543; TKG)
X,Y (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=25877200)
CSF1PO12
D1S165613
D2S44112,14
D2S133820
D3S135816,17
D5S81811,13 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=19372543; TKG)
13 (PubMed=25877200)
D7S8209,10
D8S117912,13 (ATCC; CCRID)
13 (CLS; DSMZ; Genomics_Center_BCF_Technion; PubMed=25877200)
D10S124812
D12S39116,19
D13S31711
D16S5399
D18S5115,19
D19S43313.2,14 (ATCC; CCRID; Genomics_Center_BCF_Technion; PubMed=19372543)
14 (DSMZ)
D21S1128,29
D22S104515,17
DYS39111
FGA19
Penta D2.2,11 (ATCC; CLS; Genomics_Center_BCF_Technion; PubMed=25877200)
11 (DSMZ)
Penta E16,17
TH018
TPOX8,11
vWA16 (DSMZ)
16,18 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=19372543; PubMed=25877200; TKG)

Run an STR similarity search on this cell line
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=33
https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
https://www.proteinatlas.org/learn/cellines
https://tcpaportal.org/mclp/
Publications

PubMed=6042436; DOI=10.3181/00379727-125-32327
Matsuoka Y., Moore G.E., Yagi Y., Pressman D.
Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.
Proc. Soc. Exp. Biol. Med. 125:1246-1250(1967)

PubMed=4177524; DOI=10.4049/jimmunol.101.5.1111
Matsuoka Y., Takahashi M., Yagi Y., Moore G.E., Pressman D.
Synthesis and secretion of immunoglobulins by established cell lines of human hematopoietic origin.
J. Immunol. 101:1111-1120(1968)

PubMed=5243066
Moore G.E., Kitamura H.
Cell line derived from patient with myeloma.
N. Y. State J. Med. 68:2054-2060(1968)

PubMed=18605421; DOI=10.1093/jnci/45.5.951
Ikeuchi T., Sandberg A.A.
Chromosome pulverization in virus-induced heterokaryons of mammalian cells from different species.
J. Natl. Cancer Inst. 45:951-963(1970)

DOI=10.1016/B978-0-12-427150-0.50135-2
Matsuoka Y.
Immunoglobulins.
(In) Tissue culture. Methods and applications; Kruse P.F. Jr., Patterson M.K. Jr. (eds.); pp.599-607; Academic Press; New York (1973)

PubMed=4366935
Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.
The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines and its absence in a myeloma cell line.
Cancer Res. 34:1898-1903(1974)

DOI=10.1007/978-1-4757-1647-4_11
Moore G.E.
Cell lines from humans with hematopoietic malignancies.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.299-331; Springer; New York (1975)

PubMed=6350451; DOI=10.4049/jimmunol.131.3.1201
Abrams P.G., Knost J.A., Clarke G., Wilburn S., Oldham R.K., Foon K.A.
Determination of the optimal human cell lines for development of human hybridomas.
J. Immunol. 131:1201-1204(1983)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=3893568; DOI=10.1182/blood.V66.2.444.444
Goldstein M., Hoxie J., Zembryki D., Matthews D., Levinson A.I.
Phenotypic and functional analysis of B cell lines from patients with multiple myeloma.
Blood 66:444-446(1985)

DOI=10.1016/0385-6380(87)90139-7
Mano T., Taya M., Taniguchi M., Kobayashi T.
Continuous culture of RPMI 8226 human cells.
J. Ferment. Technol. 65:425-429(1987)

PubMed=2537114; DOI=10.1182/blood.V73.2.566.566
Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M., Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M., Bataille R.
Phenotypic analysis of human myeloma cell lines.
Blood 73:566-572(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=1720489; DOI=10.1016/0145-2126(91)90110-f
Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H., Koishihara Y., Ohsugi Y., Ohno Y., Imura H.
Estimation of interleukin 6 production by reverse transcriptase-polymerase chain reaction in four human myeloma cell lines.
Leuk. Res. 15:1043-1050(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=1373872
Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille R., Theillet C., Klein B.
Mutations of the p53 gene in human myeloma cell lines.
Oncogene 7:1015-1018(1992)

PubMed=8943038; DOI=10.1073/pnas.93.24.13931
Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5
Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H.C., Bast B.J.E.G.
Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
Cancer Genet. Cytogenet. 109:99-107(1999)

PubMed=10557056; DOI=10.1038/sj.leu.2401563
Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.
Detection of MUM1/IRF4-IgH fusion in multiple myeloma.
Leukemia 13:1812-1816(1999)

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x
Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M.
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.
Br. J. Haematol. 107:392-395(1999)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=11001907; DOI=10.1182/blood.V96.7.2528
Borset M., Hjertner O., Yaccoby S., Epstein J., Sanderson R.D.
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.
Blood 96:2528-2536(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11154231; DOI=10.1182/blood.V97.2.516
Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A.
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.
Blood 97:516-522(2001)

PubMed=11157491; DOI=10.1182/blood.V97.3.729
Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Blood 97:729-736(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=14555701
Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Mol. Cancer Ther. 2:825-833(2003)

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2
Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
Am. J. Pathol. 165:71-81(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=16956823
Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.
The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.
Haematologica 91:1234-1240(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17171682; DOI=10.1002/gcc.20404
Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Genes Chromosomes Cancer 46:226-238(2007)

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell 12:131-144(2007)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011
Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.
Characterization of MYC translocations in multiple myeloma cell lines.
J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=18700954; DOI=10.1186/1755-8794-1-37
Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Lambertenghi-Deliliers G., Neri A.
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.
BMC Med. Genomics 1:37.1-37.9(2008)

PubMed=19306352; DOI=10.1002/gcc.20660
Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A., Todoerti K., Ronchetti D., Lambertenghi-Deliliers G., Neri A.
Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.
Genes Chromosomes Cancer 48:521-531(2009)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21173094; DOI=10.3324/haematol.2010.033456
Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Haematologica 96:574-582(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23074853; DOI=10.1134/S1990519X12050136
Turilova V.I., Smirnova T.D.
Karyotypic variability of human myeloma cell lines.
Tsitologiia 54:621-636(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25688540; DOI=10.1002/cyto.a.22643
Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.
A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Cytometry A 87:285-288(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

CLPUB00604
Chow S.
Targeted capture and sequencing of immunoglobulin rearrangements in multiple myeloma to enable detection of minimal residual disease.
Thesis MSc (2017), University of Toronto, Canada

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165
Clark D.J., Hu Y.-W., Bocik W., Chen L.-J., Schnaubelt M., Roberts R.R., Shah P., Whiteley G.R., Zhang H.
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
J. Proteome Res. 17:2205-2215(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=31465861; DOI=10.1016/j.jprot.2019.103504
Chanukuppa V., Paul D., Taunk K., Chatterjee T., Sharma S., Kumar S., Santra M.K., Rapole S.
XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach.
J. Proteomics 209:103504.1-103504.10(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32123307; DOI=10.1038/s41375-020-0785-1
Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B., Sirota M., Wiita A.P.
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.
Leukemia 34:2754-2765(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0003002/62
ATCC; CCL-155
ATCC; CRM-CCL-155
BCRC; 60384
CLS; 300431
Coriell; GM02132
DSMZ; ACC-402
ECACC; 87012702
IZSLER; BS TCL 92
JCRB; IFO50013
JCRB; JCRB0034
KCLB; 10155
NCBI_Iran; C210
NCI-DTP; RPMI-8226
RCB; RCB3010
TKG; TKG 0243
Cell line databases/resources CLO; CLO_0008873
CLO; CLO_0031845
MCCL; MCC:0000406
CLDB; cl4182
CLDB; cl4183
CLDB; cl4184
CLDB; cl5252
cancercelllines; CVCL_0014
CCRID; 1101HUM-PUMC000083
CCRID; 3101HUMTCHu234
Cell_Model_Passport; SIDM00087
CGH-DB; 9162-4
Cosmic-CLP; 905964
DepMap; ACH-000817
DSMZCellDive; ACC-402
IGRhCellID; RPMI8226
LINCS_LDP; LCL-2049
Lonza; 61
SKY/M-FISH/CGH; 2743
Anatomy/cell type resources BTO; BTO:0000726
Biological sample resources BioSample; SAMN03471458
BioSample; SAMN03472934
BioSample; SAMN03473581
BioSample; SAMN10988318
ENCODE; ENCBS457ZNO
ENCODE; ENCBS604KZU
CRISP screens repositories BioGRID_ORCS_Cell_line; 1003
Chemistry resources ChEMBL-Cells; CHEMBL3307732
ChEMBL-Targets; CHEMBL614882
GDSC; 905964
PharmacoDB; RPMI8226_1327_2019
PubChem_Cell_line; CVCL_0014
Encyclopedic resources Wikidata; Q54951245
Experimental variables resources EFO; EFO_0002322
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
ArrayExpress; E-TABM-937
GEO; GSM2135
GEO; GSM50198
GEO; GSM50261
GEO; GSM143340
GEO; GSM290304
GEO; GSM562819
GEO; GSM621590
GEO; GSM743461
GEO; GSM750813
GEO; GSM799349
GEO; GSM799412
GEO; GSM887548
GEO; GSM888631
GEO; GSM1153419
GEO; GSM1181289
GEO; GSM1181334
GEO; GSM1199922
GEO; GSM1199923
GEO; GSM1199924
GEO; GSM1199925
GEO; GSM1199926
GEO; GSM1199927
GEO; GSM1374855
GEO; GSM1666389
GEO; GSM1670389
GEO; GSM2124680
Polymorphism and mutation databases Cosmic; 720773
Cosmic; 724856
Cosmic; 742952
Cosmic; 759915
Cosmic; 760397
Cosmic; 875867
Cosmic; 886084
Cosmic; 888018
Cosmic; 897452
Cosmic; 905964
Cosmic; 919145
Cosmic; 974250
Cosmic; 991554
Cosmic; 999791
Cosmic; 1044255
Cosmic; 1092628
Cosmic; 1139509
Cosmic; 1139639
Cosmic; 1175858
Cosmic; 1305340
Cosmic; 1312326
Cosmic; 1762461
Cosmic; 1998470
Cosmic; 2081405
Cosmic; 2159574
Cosmic; 2367260
Cosmic; 2391801
IARC_TP53; 360
IARC_TP53; 27232
LiGeA; CCLE_817
Progenetix; CVCL_0014
Proteomic databases PRIDE; PXD001276
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD013859
PRIDE; PXD030239
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number46